Evidence map›Paper›PMID 38793069›Full record

ArticleJournal of personalized medicine2024

Follistatin as a Potential Biomarker for Identifying Metabolically Healthy and Unhealthy Obesity: A Cross-Sectional Study.

Ayşe N Erbakan, H Hicran Mutlu, Mehmet Uzunlulu, Lütfullah Caştur, Muhammet Mikdat Akbaş, Fatoş N Kaya, Mehmet Erbakan, Ferruh K İşman, Aytekin Oğuz

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ayşe N ErbakanDepartment of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.ORCID 0000-0002-9047-6808
H Hicran MutluDepartment of Family Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.ORCID 0000-0003-3712-0068
Mehmet UzunluluDepartment of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
Lütfullah CaşturDepartment of Internal Medicine, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, 34303 Istanbul, Turkey.
Muhammet Mikdat AkbaşDepartment of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.ORCID 0000-0002-8048-4281
Fatoş N KayaDepartment of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
Mehmet ErbakanDepartment of Family Medicine, Health Sciences University, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, 34865 Istanbul, Turkey.
Ferruh K İşmanDepartment of Biochemistry, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
Aytekin OğuzDepartment of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.ORCID 0000-0002-2595-5167

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolically healthy obesity (MHO) refers to obese individuals with a favorable metabolic profile, without severe metabolic abnormalities. This study aimed to investigate the potential of follistatin, a regulator of metabolic balance, as a biomarker to distinguish between metabolically healthy and unhealthy obesity. This cross-sectional study included 30 metabolically healthy and 32 metabolically unhealthy individuals with obesity. Blood samples were collected to measure the follistatin levels using an enzyme-linked immunosorbent assay (ELISA). While follistatin did not significantly differentiate between metabolically healthy (median 41.84 [IQR, 37.68 to 80.09]) and unhealthy (median 42.44 [IQR, 39.54 to 82.55]) individuals with obesity (

Indexed as

biomarkerfollistatinmetabolically healthy obesitymetabolically unhealthy obesitymetabolic healthmetabolic syndromeobesity

Identifiers

PMID38793069
PMCPMC11122067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.